Genzyme, a biotechnology company, has entered into an agreement to acquire the worldwide rights to Campath from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization
Biolase Technology, a dental laser company, and National Laser Technology have reached a final settlement agreement resolving the claims and counterclaims in the lawsuit between NLT and Biolase
Shire has previously inked a deal with Glaxosmithkline (GSK) to co-promote Vyvanse, Shire’s new drug for the treatment of attention deficit and hyperactivity disorder. The agreement is expected
According to reports, Sanofi has approached Solvac, the family-owned holding vehicle that controls 30% of Solvay, and made an offer of E7.2 billion or E85 per share for
The pharmaceutical industry has been targeted by the online financial community MeettheBoss. MeettheBoss, originally focused on the financial services sector, has launched a new section dedicated to the
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, has received marketing authorization from the Australian Therapeutic Goods Administration for Emerflu, the company’s pandemic influenza vaccine for human use.
Dyax, a US-based clinical stage biopharmaceutical company, has announced that it is eliminating 60 positions from various departments within the company to focus its resources on the commercialization
By entering the second phase, Merck gains access to a new multi-million member library of small molecule drug candidates. In addition, this development triggers the payment of an
Mr Newton most recently served in various executive officer roles at Synenco Energy, from 2004 to 2008, including as president and CEO; president and COO; and executive vice
The MRSAid photodisinfection system is designed to reduce Methicillin-resistant Staphylococcus aureus (MRSA) colonization of the anterior nasal passages, the company said. Carolyn Cross, chairman and CEO of Ondine,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.